PTI-1
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | 1400742-46-2 |
| Chemical and physical data | |
| Formula | C21H29N3S |
| Molar mass | 355.54 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
PTI-1 is an indole-based synthetic cannabinoid.[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-2. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.[2][3][4][5]
See also
References
- ↑ "PTI-1". Cayman Chemical. Retrieved 8 July 2015.
- ↑ Julia Adam-Worrall, et al. (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor. Patent US 7700634, priority date 5 March 2004
- ↑ Paul David Ratcliffe, et al. Indole Derivatives. Patent US 7763732, priority date 24 August 2005
- ↑ Julia Adam, et al. Indole Derivatives. Patent WO 2008/101995, priority date 22 February 2007
- ↑ Takao Kiyoi, et al. Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists. Bioorganic and Medicinal Chemistry Letters 2011; 21(6):1748-1753. doi: 10.1016/j.bmcl.2011.01.082
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.